Issue 4/2004
Content (12 Articles)
Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer
Robert J. Morgan Jr., Timothy W. Synold, David Gandara, Franco Muggia, Sidney Scudder, Eddie Reed, Kim Margolin, James Raschko, Lucille Leong, Stephen Shibata, Merry Tetef, Steven Vasilev, Kathryn McGonigle, Jeff Longmate, Yun Yen, Warren Chow, George Somlo, Mary Carroll, James H. Doroshow
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
Catherine Dutreix, Bin Peng, Guenther Mehring, Michael Hayes, Renaud Capdeville, Rolf Pokorny, Michael Seiberling
Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy
Gareth J. Veal, Martin W. English, Richard G. Grundy, Cay Shakespeare, Adam Glaser, Fiona Waters, Vicky Holden, Anne O’Meara, Antony Michalski, Karen Howe, Sue Cole, Alan V. Boddy
Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase
Hong Bing Deng, Mahesha Adikari, Hemant K. Parekh, Henry Simpkins
Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors
Hai T. Tran, George R. Blumenschein Jr., Charles Lu, Christina A. Meyers, Vali Papadimitrakopoulou, Frank V. Fossella, Ralph Zinner, Timothy Madden, Lori G. Smythe, Vinay K. Puduvalli, Reggie Munden, Mylene Truong, Roy S. Herbst
Ascorbate modulation of H2O2 and camptothecin-induced cell death in Jurkat cells
Alain-Théophile Sané, André M. Cantin, Benoit Paquette, J. Richard Wagner
Involvement of oxidative stress and caspase activation in paclitaxel-induced apoptosis of primary effusion lymphoma cells
Yi-Fen Wang, Chang-Yu Chen, Su-Fang Chung, Yee-Hsuan Chiou, Horng-Ren Lo
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer
Yun Yen, Kim Margolin, James Doroshow, Mayer Fishman, Bonny Johnson, Caroline Clairmont, Dan Sullivan, Mario Sznol
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line
Melinda M. Mortenson, Michael G. Schlieman, Subbulakshmi Virudachalam, Richard J. Bold
The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells
Aimee K. Bence, Cynthia A. Mattingly, Thomas G. Burke, Val R. Adams
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma
Phillip B. Storm, Violette M. Renard, John L. Moriarity, Betty Tyler, Robb E. Wilentz, Henry Brem, Jon D. Weingart
A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days
Howard H. Bailey, George Wilding, Kendra D. Tutsch, Rhoda Z. Arzoomanian, Dona Alberti, Chris Feierabend, Kris Simon, Rebecca Marnocha, Sarah A. Holstein, Jan Stewart, Kriste A. Lewis, Raymond J. Hohl